Govt To Shut 2 Pharma PSUs, Disinvest Hindustan Antibiotics, 2 Other: Minister Informs Parliament
- byDoctor News Daily Team
- 26 July, 2025
- 0 Comments
- 0 Mins

New Delhi: The government has decided to close two pharma public sector undertakings and disinvest the other three including Hindustan Antibiotics Ltd (HAL), Parliament was informed on Tuesday.
The information to this effect came during a recent Lok Sabha session, wherein, the Minister of Chemicals and Fertilisers D V Sadananda Gowda was asked whether the Government has taken any steps for the sale of pharma PSUs including the large tract of commercial lands belonging to Pharma PSUs in the country like the IDPL located at Nandambakkam, Chennai.
He was further asked about the effective steps taken by the Government to protect the interests of workers of such Government Pharma companies
Responding to the queries, Gowda said, "The Department of Pharmaceuticals has five public sector undertakings (PSUs). Out of the five PSUs, the government has taken a decision to close two pharma PSUs, namely Indian Drugs & Pharmaceuticals Ltd (IDPL) and Rajasthan Drugs & Pharmaceuticals Ltd (RDPL)."
Also Read: Indian Pharma Industry Expected To Reach USD 130 Billion By 2030: D V Sadananda Gowda
The government has also decided to strategically disinvest the other three -- Hindustan Antibiotics Ltd (HAL), Bengal Chemicals & Pharmaceuticals Ltd (BCPL), and Karnataka Antibiotics & Pharmaceutical Ltd (KAPL), he added.
The government has offered voluntary retirement benefits to all employees of IDPL and RDPL, Gowda said, adding that the land belonging to IDPL at Nandambakkam, which is a subsidiary of IDPL, the land is leasehold from the Government of Tamil Nadu at free of cost.
"However, the Committee of Ministers constituted on September 9, 2019, will take necessary decisions pertaining to closure/strategic sale of the pharma public sector undertakings, including the sale of assets and clearance of outstanding liabilities," Gowda added in his reply to the questions raised in the Parliament.
Read also: Indian Pharma Industry Expected To Reach USD 130 Billion By 2030: D V Sadananda Gowda
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Chennai: Fortis Healthcare Opens 250-Bedded 2nd Mu...
- 06 July, 2025
New Lab-On-A-Chip, Cheaper, Faster, On The Spot Di...
- 06 July, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!